title: Prostaglandin E2 alleviates cyclosporin A-induced bone loss in the rat.
abstract: Cyclosporine A (CsA) administered to the male and female rat produces high-turnover osteopenia. Prostaglandins have both bone-resorbing and bone-forming properties, but administration of prostaglandin E2 (PGE2) to the rat in vivo produces a net increase in cancellous bone. To investigate the effects of PGE2 on CsA-induced alteration in bone mass, 43 male Sprague-Dawley rats (9 weeks old) were administered 15 mg/kg of CsA by oral gavage and/or 6 mg/kg of PGE2 by subcutaneous injection daily for 21 days according to the following protocol: group A was an age-matched control; group B received CsA only; group C received PGE2 only; and group D received CsA and PGE2. Serum was assayed on days 0, 7, 14, and 21 for bone gla protein (BGP), PTH, and 1,25-dihydroxyvitamin D [1,25-(OH)2D]. A computerized image analysis system was used for bone histomorphometry of the proximal tibial metaphysis after double tetracycline labeling. Compared to control animals (group A), treatment with CsA alone (group B) and PGE2 alone (group C) significantly elevated BGP levels. Combination therapy (group D) resulted in BGP levels that were significantly higher on days 7 and 14 than with either agent alone. 1,25-(OH)2D was significantly elevated in the CsA group only (group B). Therapy with CsA alone (group B) resulted in a significant osteopenia. The concurrent administration of PGE2 with CsA (group D) alleviated the altered bone mass induced by CsA alone by adding a significant amount of additional bone. This report confirms and extends the current knowledge of the different effects of CsA and PGE2 on bone mineral metabolism and demonstrates that PGE2 can alleviate the deleterious effects of CsA on bone.
authors.affiliation: Division of Endocrinology and Metabolism, Albert Einstein Medical Center, Philadelphia, Pennsylvania.
authors.forename: I A
authors.initials: IA
authors.lastname: Katz
authors.forename: W S
authors.initials: WS
authors.lastname: Jee
authors.forename: I I
authors.initials: II
authors.lastname: Joffe
authors.forename: B
authors.initials: B
authors.lastname: Stein
authors.forename: M
authors.initials: M
authors.lastname: Takizawa
authors.forename: T W
authors.initials: TW
authors.lastname: Jacobs
authors.forename: R
authors.initials: R
authors.lastname: Setterberg
authors.forename: B Y
authors.initials: BY
authors.lastname: Lin
authors.forename: L Y
authors.initials: LY
authors.lastname: Tang
authors.forename: H Z
authors.initials: HZ
authors.lastname: Ke
mesh_terms: D000284:Administration, Oral; D000818:Animals; D015519:Bone Density / Q000187:drug effects*; D001851:Bone Diseases, Metabolic / Q000139:chemically induced / Q000188:drug therapy* / Q000503:physiopathology; D002117:Calcitriol / Q000097:blood; D016572:Cyclosporine / Q000633:toxicity*; D015232:Dinoprostone / Q000494:pharmacology*; D005260:Female; D007091:Image Processing, Computer-Assisted; D008297:Male; D015675:Osteocalcin / Q000097:blood; D010281:Parathyroid Hormone / Q000097:blood; D051381:Rats; D017207:Rats, Sprague-Dawley
chemical_list: D010281:Parathyroid Hormone; D015675:Osteocalcin; D016572:Cyclosporine; D002117:Calcitriol; D015232:Dinoprostone